Holen Sie sich die Stockscreener-App
8.40
3.56%
-0.31
Handel nachbörslich:
8.40
Schlusskurs vom Vortag:
$8.71
Offen:
$8.75
24-Stunden-Volumen:
34,077
Relative Volume:
0.56
Marktkapitalisierung:
$97.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.60%
1M Leistung:
-2.33%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.07
$8.75
1-Wochen-Bereich:
$8.07
$9.10
52-Wochen-Spanne:
$7.24
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Firmenname
Imagenebio Inc
Sektor
Branche
Telefon
857-343-8292
Adresse
50 NORTHERN AVE., BOSTON
Vergleichen Sie IMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
8.40 | 97.39M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Eingeleitet | Leerink Partners | Outperform |
Imagenebio Inc Aktie (IMA) Neueste Nachrichten
ImageneBio Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update - Defense World
Miragene Inc. Announces Extension of Key Service Agreement - MarketScreener
Imagenebio Inc elects not to renew agreement with MirageneSEC filing - MarketScreener
ImageneBio IncOn Oct 23, Elects Not To Renew Agreement With MirageneSEC Filing - TradingView
ImageneBio Extends Agreement with Miragene Inc. - TipRanks
Leerink Partners initiates Imagene Bio stock with Outperform rating By Investing.com - Investing.com South Africa
Leerink Partners initiates Imagene Bio stock with Outperform rating - Investing.com India
Leerink Partners Initiates ImageneBio at Outperform With $30 Price Target - MarketScreener
This Albemarle Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Leerink Partners Initiates Coverage on ImageneBio (IMA) with Out - GuruFocus
ImageneBio’s IMG-007: A Promising Blockbuster in Atopic Dermatitis with Strategic Leadership and Competitive Edge - TipRanks
ImageneBio initiated with an Outperform at Leerink - TipRanks
Weiss Ratings Initiates Coverage on ImageneBio (NASDAQ:IMA) - Defense World
ImageneBio, Inc.Common Stock (Nasdaq:IMA) Stock Quote - FinancialContent
ImageneBio appoints CEO Kristin Yarema as interim principal financial officer By Investing.com - Investing.com Nigeria
ImageneBio, Inc. Appoints Kristin Yarema as Interim Principal Financial Officer, Effective October 21, 2025 - MarketScreener
ImageneBio appoints CEO Kristin Yarema as interim principal financial officer - Investing.com
ImageneBio Appoints New Interim Financial Officer - TipRanks
OX40 Targeted Therapy Clinical Trials Anti OX40 Antibody Development Market Opportunity Insight 2026 - GlobeNewswire Inc.
ImageneBio CFO Jotin Marango resigns, company to begin search for successor - Investing.com Australia
ImageneBio Charts New Course Following Merger Completion - AD HOC NEWS
ImageneBio CFO Resignation Announced - TipRanks
ImageneBio (NASDAQ:IMA) Cut to “Hold” at Zacks Research - Defense World
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to Hold - Defense World
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - msn.com
ImageneBio (NASDAQ:IMA) Stock Price Down 1.2% – Here’s Why - Defense World
ImageneBio files to sell 2.51M shares of common stock for holders - MSN
ImageneBio (NASDAQ:IMA) Shares Down 1.3%Should You Sell? - MarketBeat
ImageneBio (NASDAQ:IMA) Shares Down 1.3% – Should You Sell? - Defense World
HUTCHMED Reports 2025 Interim Results - GlobeNewswire
Ikena Oncology (IMA) Projected to Post Quarterly Earnings on Thursday - Defense World
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
Q3 EPS Estimates for Ikena Oncology Lifted by William Blair - Defense World
William Blair Comments on Ikena Oncology FY2029 Earnings - Defense World
ImageneBio Approves 2025 Inducement Plan for Employees - The Globe and Mail
ImageneBio board approves 2025 inducement plan for new employee equity awards - Investing.com Australia
ImagenBio Adopts 2025 Equity Inducement Plan to Retain Top Talent - AInvest
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ImageneBio Grants Massive $9.6M Equity Package: New CEO Gets 436K Stock Options, 153K RSUs - Stock Titan
Imagenebio shares rise 7.26% premarket after insider bought shares worth $7.999.924. - AInvest
Insider Transactions Reported | ImageneBio(IMA)saw insider trading activity on 7/30/2025 - AInvest
Ikena Oncology Completes Merger, Becomes ImageneBio, Inc. - The Globe and Mail
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA) - MarketScreener
IMA Stock Price and Chart — NASDAQ:IMA - TradingView
Finanzdaten der Imagenebio Inc-Aktie (IMA)
Es liegen keine Finanzdaten für Imagenebio Inc (IMA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):